ClinicalTrials.gg
Not yet recruitingNCT07750600Updated Aug 6, 2026

AI-Assisted Clinical Documentation in Nurse-Led Telehealth Contacts

An interventional study of AI-assisted clinical documentation (ambient AI scribe, Tandem Health) in AI-assisted Documentation, sponsored by Hospital District of Helsinki and Uusimaa. Not yet recruiting at 1 site in Finland. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Hospital District of Helsinki and Uusimaa · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Sex
All
01

Study summary

Background: No randomized controlled trial evidence currently exists on the effectiveness of ambient artificial intelligence (AI)-assisted clinical documentation.

Objective: To evaluate the effect of AI-assisted documentation on nurse productivity, professional experience, and documentation quality in nurse-led telehealth (telephone and chat) contacts in Finnish primary care (Wellbeing Services County of Kanta-Häme, OmaHäme).

Methods: In this randomized, open-label, repeated crossover trial, approximately 64 nurses are allocated 1:1 to an ABAB or BABA sequence of four two-week periods (A = AI-assisted documentation, B = standard manual documentation) over eight weeks. The primary outcome is the number of patient contacts handled per nurse, analyzed with a generalized linear mixed-effects model for count data with nurse as a random effect; the treatment effect is expressed as an incidence rate ratio (IRR). A Monte Carlo simulation-based power analysis indicated 85% power to detect an IRR of 1.15 at a two-sided alpha of 0.05. Secondary outcomes include self-reported work-time savings, nurse experience and satisfaction, and patient satisfaction. Discrepancies between AI-generated draft notes, and final signed notes are analyzed to characterize the frequency, type, and clinical criticality of AI errors and omissions.

The trial is investigator-initiated (OmaHäme, HUS Helsinki University Hospital, University of Helsinki) and funded by the Strategic Research Council (GAINS project). The technology provider (Tandem Health) supplies the technical solution and participates in study design and manuscript preparation; responsibility for the study design, data analysis, and conclusions rests with the academic study group.

02

Conditions studied

  • AI-assisted Documentation
03

In context

Lead sponsor

Hospital District of Helsinki and Uusimaa is the lead sponsor of 14 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nurses at OmaHäme (Wellbeing Services County of Kanta-Häme) handling telephone or chat patient contacts

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Sequence ABAB

    Nurses randomized to begin with AI-assisted documentation (A), alternating with standard manual documentation (B) in four consecutive two-week periods (A-B-A-B).

    Other: AI-assisted clinical documentation (ambient AI scribe, Tandem Health)

  • Experimental
    Sequence BABA.

    Nurses randomized to begin with standard manual documentation (B), alternating with AI-assisted documentation (A) in four consecutive two-week periods (B-A-B-A).

    Other: AI-assisted clinical documentation (ambient AI scribe, Tandem Health)

Interventions

  • OtherAI-assisted clinical documentation (ambient AI scribe, Tandem Health)

    During AI-assisted periods, nurses use an ambient AI scribe that transcribes the patient contact and generates a draft clinical note, which the nurse reviews, edits, and approves. During control periods, nurses document contacts manually according to standard practice. All other aspects of care follow normal clinical routines.

06

What researchers measure

Primary outcomes

  1. Number of patient contacts handled per nurse per working day/hour.

    Count of telehealth (telephone/chat) contacts handled per nurse per working day/hour during time of excess demand extracted from routine service data.

    Time frame: Daily/hourly, over four 2-week periods (8 weeks).

Secondary outcomes

  1. Self-reported work-time savings.

    Nurses' estimate of the effect of AI-assisted documentation on time spent on documentation, assessed with a study-specific end-of-study questionnaire (5-point Likert scale).

    Time frame: Week 8 (end of study).

  2. Nurse-reported experience and satisfaction.

    Perceived workflow, efficiency, workload, and job satisfaction, assessed with study-specific baseline and end-of-study questionnaires (5-point Likert scales).

    Time frame: Baseline (week 0) and week 8 (end of study).

07

Study locations

1 site
  • Wellbeing Services County of Kanta-Häme (OmaHäme)
    Hämeenlinna, Finland
08

References and documents

Individual participant data

Plan to share: No — Individual-level data contain sensitive personal and patient data processed under the GDPR and the Finnish Act on the Secondary Use of Health and Social Data; data are stored in the HUS Acamedic secure environment and cannot be shared as individual participant data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Oct 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2026
First posted
Aug 6, 2026
StartEst.
Sep 2026
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07750600
Lead sponsor
Hospital District of Helsinki and Uusimaa
Collaborators
Tandem Health AB (technology provider), University of Helsinki, Wellbeing Services County of Kanta-Häme (OmaHäme)
Responsible party
Ville Vartiainen (Docent, MD, PhD, MSc, Researcher, Hospital District of Helsinki and Uusimaa) — Principal investigator
First posted
Aug 6, 2026
Start date
Sep 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 6, 2026

Study contacts

Ville Vartiainen, MD, PhD, MSc
Contact
ville.vartiainen@hus.fi
+358 50 430 6414

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion